Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

• Egile Nagusiak: Marco Tuccori (Egilea), Sara Ferraro (Egilea), Irma Convertino (Egilea), Emiliano Cappello (Egilea), Giulia Valdiserra (Egilea), Corrado Blandizzi (Egilea), Fabrizio Maggi (Egilea), Daniele Focosi (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SA...